Clear Creek Financial Management LLC Sells 558 Shares of Pfizer Inc. (NYSE:PFE)

Posted by on Apr 2nd, 2023

Clear Creek Financial Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 2.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,287 shares of the biopharmaceutical company’s stock after selling 558 shares during the quarter. Clear Creek Financial Management LLC’s holdings in Pfizer were worth $988,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Community Bank of Raymore grew its stake in shares of Pfizer by 270.2% during the 4th quarter. Community Bank of Raymore now owns 25,800 shares of the biopharmaceutical company’s stock worth $1,322,000 after acquiring an additional 18,830 shares in the last quarter. West Wealth Group LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $230,000. Red Door Wealth Management LLC grew its stake in shares of Pfizer by 5.8% during the 4th quarter. Red Door Wealth Management LLC now owns 122,364 shares of the biopharmaceutical company’s stock worth $6,270,000 after acquiring an additional 6,688 shares in the last quarter. Landmark Financial Advisors LLC grew its stake in shares of Pfizer by 6.5% during the 4th quarter. Landmark Financial Advisors LLC now owns 7,509 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 460 shares in the last quarter. Finally, Inlet Private Wealth LLC grew its stake in shares of Pfizer by 8.2% during the 4th quarter. Inlet Private Wealth LLC now owns 95,683 shares of the biopharmaceutical company’s stock worth $4,903,000 after acquiring an additional 7,231 shares in the last quarter. 67.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PFE shares. Atlantic Securities decreased their price target on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research note on Wednesday, February 1st. UBS Group set a $45.00 price objective on Pfizer in a report on Tuesday, March 14th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price objective for the company in a report on Tuesday, February 7th. JPMorgan Chase & Co. set a $45.00 price objective on Pfizer in a report on Monday, February 27th. Finally, Credit Suisse Group cut their price objective on Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $50.38.

Insider Transactions at Pfizer

In related news, major shareholder Pfizer Inc purchased 1,811,594 shares of the firm’s stock in a transaction that occurred on Friday, March 17th. The shares were bought at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the completion of the transaction, the insider now owns 5,952,263 shares of the company’s stock, valued at $16,428,245.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Pfizer Trading Up 1.0 %

Shares of Pfizer stock opened at $40.80 on Friday. The business has a fifty day simple moving average of $41.98 and a two-hundred day simple moving average of $45.61. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32. The company has a market capitalization of $230.29 billion, a price-to-earnings ratio of 7.45, a P/E/G ratio of 1.36 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00.

Pfizer (NYSE:PFE – Get Rating) last posted its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. During the same quarter last year, the firm earned $1.08 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 3.3 EPS for the current year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.